Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study

被引：10

作者：

Fasching, P. A. ^{[1
]}

Fehm, T. ^{[2
,39
]}

Kellner, S. ^{[3
]}

de Waal, J. ^{[3
]}

Rezal, M. ^{[4
]}

Baler, B. ^{[3
]}

Baake, G. ^{[5
]}

Kolberg, H. -C ^{[6
]}

Guggenberger, M. ^{[7
]}

Warm, N. ^{[3
,8
,9
]}

Harbeck, N. ^{[29
]}

Wuerstlein, R. ^{[10
]}

Deuker, J. -U ^{[11
,21
]}

Dall, P. ^{[12
,31
]}

Richter, B. ^{[32
]}

Wachsmann, G. ^{[13
]}

Brucker, C. ^{[14
]}

Siebers, J. W. ^{[15
]}

Fersis, N. ^{[16
]}

Kuhn, T. ^{[17
]}

Wolf, C. ^{[18
]}

Vollert, H. -W ^{[19
]}

Breitbach, G. -P ^{[20
,22
]}

Janni, W. ^{[21
]}

Landthaler, R. ^{[22
]}

Kohls, A. ^{[23
,33
]}

Rezek, D. ^{[24
,28
]}

Nosslet, T. ^{[25
,27
]}

Fischer, G. ^{[26
]}

Henschen, S. ^{[28
]}

Praetz, T. ^{[29
]}

Heyl, V. ^{[35
]}

Kuehn, T. ^{[30
,32
]}

Krauss, T. ^{[31
]}

Thomssen, C. ^{[32
]}

Kuemmel, S. ^{[33
]}

Hohn, A. ^{[34
]}

Tesch, H. ^{[35
]}

Mundhenke, C. ^{[31
]}

Hein, A. ^{[1
,33
]}

Rauh, C. ^{[1
]}

Bayer, C. M. ^{[1
]}

Jacob, A. ^{[37
]}

Schmidt, K. ^{[37
]}

Belleville, E. ^{[31
]}

Hadji, P. ^{[38
]}

Wallwiener, D. ^{[39
]}

Grischice, E. -M ^{[36
,39
]}

Beckmann, M. W. ^{[1
]}

Brucker, S. Y.

机构：

[1] Univ Erlangen Nurnberg, Univ Brustzentrum Franken, Frauenklin, Comprehens Canc Ctr Erlangen EMN,Univ Klinikum Er, D-91054 Erlangen, Germany

[2] Univ Frauenklin Dusseldorf, Dusseldorf, Germany

[3] Frauenklin Klinikum Dachau, Dachau, Germany

[4] Luisenkrankenhaus Dusseldorf, Dusseldorf, Germany

[5] Klinikum Pinneberg, Pinneberg, Germany

[6] Marienhosp Bottrop, Bottrop, Germany

[7] Klinikum Tuttlingen, Tuttlingen, Germany

[8] Univ Frauenklin Koln, Brustzentrum, Cologne, Germany

[9] Klinken Stadt Koln gGmbH Holweide, Brustzentrum, Cologne, Germany

[10] Univ Munich, Brustzentrum, Frauenkliniken Grosshadern & Maistr Innenstad, Munich, Germany

[11] Klinikum Luneburg, Frauenklin, Luneburg, Germany

[12] Elblandkliniken Meissen Radebeul Standort Radebeu, Radebeul, Germany

[13] Kreiskrankenhaus Boblingen, Boblingen, Germany

[14] Paracelsus Med Privatuniv, Univ Klin Frauenheilkunde, Nurnberg, Germany

[15] St Josefklin Offenburg, Frauenklin, Offenburg, Germany

[16] Klinikum Bayreuth GmbH, Comprehens Canc Ctr Erlangen EMN, Frauenklin, Bayreuth, Germany

[17] Karl Olga Krankenhaus, Stuttgart, Germany

[18] Med Zentrurn Ulm, Ulm, Germany

[19] Klinikum Friedrichshafen, Friedrichshafen, Germany

[20] Stadt Klinikum Neunkirchen Gynakol & Geburtshilfe, Neunkirchen, Germany

[21] Univ Ulm Klinikum, Frauenklin, Ulm, Germany

[22] Gynakol Praxis Kreisklin, Krumbach, Germany

[23] Evangel Krankenhaus Ludwigsfelde Teltow, Ludwigsfelde, Germany

[24] Marien Hosp Wesel, Wesel, Germany

[25] Frauenklin Kreiskrankenhaus Hameln, Hameln, Germany

[26] Landkreis Mittweida Krankenhaus gGmbH, Mittweida, Germany

[27] Johanniter Krankenhaus Genthin Stendal gGmbH, Stendal, Germany

[28] Praxis Dr Praetz, Bad Mergenlheim, Germany

[29] Asklepios Paulinen Klin Wiesbaden, Wiesbaden, Germany

[30] Stadt Kliniken Esslingen aN, Frauenklin, Esslingen, Germany

[31] Frauenklin Lippe, Lippe, Germany

[32] Univ Klin Halle Wittenberg, Frauenklin, Halle, Germany

[33] Evang Huyssens Stiftung Knappschaft GmbH, Kliniken Essen Mitte, Brustzentrum, Essen, Germany

[34] Kreiskrankenhaus Rendsburg, Rendsburg, Germany

[35] Onkol Bethanien, Frankfurt, Germany

[36] Univ Klinikum Schleswig Holstein Campus Kiel, Kiel, Germany

[37] Novartis Pharma GmbH, Nurnberg, Germany

[38] Krankenhaus NW Frankfurt, Klin Gynakol & Gebursthilfe, Frankfurt, Germany

[39] Univ Frauenklin Tubingen, Tubingen, Germany

来源：

GEBURTSHILFE UND FRAUENHEILKUNDE | 2014年 / 74卷 / 12期

关键词：

breast cancer; aromatase inhibitor; compliance; endocrine therapy; ADJUVANT ENDOCRINE THERAPY; PATIENTS ANASTROZOLE COMPLIANCE; RANDOMIZED-TRIAL; TAMOXIFEN THERAPY; PACT PROGRAM; WOMEN; EXEMESTANE; COMBINATION; ADHERENCE;

D O I：

10.1055/s-0034-1383401

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Introduction: The EvaluateTM study (Evaluation of therapy management and patient compliance in postmenopausal hormone receptor-positive breast cancer patients receiving letrozole treatment) is a prospective, non-interventional study for the assessment of therapy management and compliance in the routine care of postmenopausal women with invasive hormone receptor-positive breast cancer receiving letrozole. The parameters for inclusion in the study are presented and discussed here. Material and Methods: Between January 2008 and December 2009 a total of 5045 patients in 310 study centers were recruited to the EvaluateTM study. Inclusion criteria were hormone receptor-positive breast cancer and adjuvant treatment or metastasis. 373 patients were excluded from the analysis for various reasons. Results: A total of 4420 patients receiving adjuvant treatment and 252 patients with metastasis receiving palliative treatment were included in the study. For 4181 patients receiving adjuvant treatment, treatment with the aromatase inhibitor letrozole commenced immediately after surgery (upfront). Two hundred patients had initially received tamoxifen and started aromatase inhibitor treatment with letrozole at 1-5 years after diagnosis (switch), und 39 patients only commenced letrozole treatment 5-10 years after diagnosis (extended endocrine therapy). Patient and tumor characteristics were within expected ranges, as were comorbidities and concurrent medication. Conclusion: The data from the EvaluateTM study will offer a good overview of therapy management in the routine care of postmenopausal women with hormone receptor-positive breast cancer. Planned analyses will look at therapy compliance and patient satisfaction with how information is conveyed and the contents of the conveyed information.

引用

页码：1137 / 1143

页数：7

共 50 条

[1] Maintenance hormone therapy with letrozole after first-line chemotherapy in postmenopausal patients with hormone receptor-positive metastatic breast cancer
Borrego, M. Ruiz
De la Haba, J.
Morales, S.
Ramos, M.
Velasco, A.
Mendez, M.
Carabantes, F.
Barnadas, A.
Garcia, M.
Moreno, J. A.
EJC SUPPLEMENTS, 2005, 3 (02): : 117 - 117
[2] Maintenance hormone therapy with letrozole after first-line chemotherapy in postmenopausal patients with hormone receptor-positive metastatic breast cancer
Ruiz, Manuel
De la Haba, Juan
Morales, Serafin
Ramos, Manuel
Velasco, Amlia
Mendez, Miguel
Carabantes, Francisco
Barnadas, Agusti
Garcia, Maria
Moreno, Jose A.
ANNALS OF ONCOLOGY, 2004, 15 : 35 - 35
[3] Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
Johnston, Stephen
Pippen, John, Jr.
Pivot, Xavier
Lichinitser, Mikhail
Sadeghi, Saeed
Dieras, Veronique
Gomez, Henry Leonidas
Romieu, Gilles
Manikhas, Alexey
Kennedy, M. John
Press, Michael F.
Maltzman, Julie
Florance, Allison
O'Rourke, Lisa
Oliva, Cristina
Stein, Steven
Pegram, Mark
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) : 5538 - 5546
[4] Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer
Lippman, Marc
LANCET ONCOLOGY, 2019, 20 (03): : 312 - 313
[5] Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer
Connolly, Roisin M.
Stearns, Vered
ONCOLOGY-NEW YORK, 2013, 27 (06): : 571 - +
[6] Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea
Beom, Seung Hoon
Oh, Jisu
Kim, Tae-Yong
Lee, Kyung-Hun
Yang, Yaewon
Suh, Koung Jin
Moon, Hyeong-Gon
Han, Sae-Won
Oh, Do-Youn
Han, Wonshik
Kim, Tae-You
Noh, Dong-Young
Im, Seock-Ah
CANCER RESEARCH AND TREATMENT, 2017, 49 (02): : 454 - 463
[7] Adjuvant Systemic Therapy for Postmenopausal, Hormone Receptor-Positive Early Breast Cancer
Johnston, Stephen R. D.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (01) : 89 - 102
[8] Intermittent letrozole as adjuvant treatment in postmenopausal hormone-receptor positive early breast cancer patients
Balduzzi, A.
Bagnardi, V.
Volpe, S.
Cancello, G.
Iorfida, M.
Dellapasqua, S.
Sandri, M.
Goldhirsch, A.
Colleoni, M.
CANCER RESEARCH, 2013, 73
[9] Comparative efficacy study of 5-year letrozole or anastrozole in postmenopausal hormone receptor-positive early breast cancer
Sendur, M. A. N.
Aksoy, S.
Zengin, N.
Altundag, K.
JOURNAL OF BUON, 2013, 18 (04): : 838 - 844
[10] Treatment interruption and discontinuation of hormonal therapy in hormone receptor-positive breast cancer patients
Mao, Daqin
Hachem, Hilal
Chang, Hong
Dima, Danai
Dower, Joshua
Wismer, Michael
Erban, John K.
Freund, Karen M.
Parsons, Susan K.
BREAST CANCER RESEARCH AND TREATMENT, 2020, 184 (03) : 665 - 674

← 1 2 3 4 5 →